Tegoprubart (AT-1501) is an experimental humanized monoclonal antibody that inhibits CD40L. It is developed for ALSMeglio, Marco. "Tegoprubart Demonstrates Safety, Target Engagement of ALS Markers in Phase 2 Study." Neurology Times, 3 Nov. 2022, p. NA. Gale Academic OneFile, link.gale.com/apps/doc/A762611032/AONE?u=anon~b1a7e306&sid=googleScholar&xid=733a3e0e. Accessed 4 Dec. 2023. and transplant rejection.
Eledon Pharmaceuticals In March 2026, clinical data presented at the Advanced Technologies and Treatments for Diabetes (ATTD) conference demonstrated that tegoprubart, a monoclonal antibody inhibiting the CD40 ligand, enabled 100% insulin independence in ten evaluable patients following allogeneic islet transplantation. The pilot study, conducted at the University of Chicago Medicine, utilized tegoprubart as part of a calcineurin inhibitor-free regimen, resulting in a mean HbA1c of 5.35% without evidence of nephrotoxicity or neurotoxicity typically associated with standard immunosuppressants.
References